AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD)

PHASE2UnknownINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

August 2, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Autism Spectrum Disorder (ASD)
Interventions
DRUG

AB-2004

Taken 3 times daily with food

DRUG

Placebo

Take 3 times daily with food

Trial Locations (24)

1010

Optimal Clinical Trials, Grafton

2050

Brain Mind Centre, Sydney

2145

Westmead Children's Hospital, Sydney

3052

Murdoch Children's Research Institute, Parkville

3186

Monash Kids Research, Clayton

4101

Children's Health Queensland Hospital, South Brisbane

10021

Spectrum Neuroscience and Treatment Institute, New York

10962

Nathan S. Kline Institute for Psychiatric Research, Orangeburg

32256

CNS Solutions, Jacksonville

32801

CNS Solutions, Orlando

33613

University of South Florida, Tampa

36303

Harmonex Neuroscience Research, Dothan

37212

Vanderbilt University Medical Center, Nashville

43210

Ohio State University, Columbus

60563

Baber Research, Naperville

65201

University of Missouri, Thompson Center for Autism and Neurodevelopmental Disorders, Columbia

75243

Relaro Medical Trials, Dallas

80112

IMMUNOe Research Centers, Centennial

85006

Southwestern Autism Research and Resource Center, Phoenix

85724

University of Arizona, Tucson

89128

Clinical Research of Southern Nevada, Las Vegas

91361

Cortica Westlake, Westlake Village

94903

Cortica Marin, San Rafael

06519

Yale University, New Haven

Sponsors
All Listed Sponsors
lead

Axial Therapeutics, Inc.

INDUSTRY

NCT04895215 - AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) | Biotech Hunter | Biotech Hunter